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ABSTRACT. Background: We explored carer motivation for seeking participation for a relative 
in an Alzheimer’s disease (AD) clinical drug trial, to assess impressions of the value of trial 
participation. We also surveyed the carers of patients who did not meet study entry screen- 
ing criteria to see if our conduct of the screening visit was acceptable and ethical. Method: A 
retrospective questionnaire was sent to the carers of 36 randomized participants and 22 car- 
ers of patients who did not meet study entry screening criteria for an AD clinical treatment 
trial. Results: Twenty-nine (81%) of the trial participant carers and 15 (68%) of carers of the 
group who did not meet study entry criteria returned their questionnaires with sufficient 
information for analysis. The prime motivators in seeking trial participation were to help 
their relative feel better and live longer, to contribute to  medical science, to improve the 
health of others, and the hope of a cure. Carers of both groups found research staff sup- 
portive and would recommend trial participation to others. Conclusions: Even though trial 
participation is onerous and patients were generally perceived by carers as not having 
improved, both the screening visit and participation in the trial itself were seen as positive 
experiences and the expectations of carers were met. 
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The motivations and expectations of 
research participants are relatively unex- 
plored areas, a search of the literature 
producing few reports on these subjects. 
Studies of dementia (Elad et al., 2000; 
Karlawish et al., ZOOl), cancer (Madsen 
et al., 2000), and outpatient (Madsen et 
al., 1999) research volunteers found that 
participation was motivated largely by 
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altruism-a wish to help future patients 
and science in general (Elad et al., 2000; 
Madsen et al., 2000; Terenius, 2000). Car- 
ers of patients in dementia trials have 
less “burn out,” and demonstrate a high- 
er level of hope than those who decline 
participation (Elad et al., 2000). They 
have a need to do  “absolutely anything 
to  improve the plight of their loved one” 
coupled with a hope that their own bur- 
den of care may be eased through 
improving the quality of life of the 
patient (Karlawish et al., 2001). Other 
factors influencing carer participation 
include trust in the physician (Karlawish 
et al., 2001), a wish to be closely moni- 
tored (Madsen et al., ZOOO), family pres- 
sure (Elad et al., 2000), and access to 
new drugs (Karlawish et al., 2001; Mad- 
sen et al., 2000). 
The availability of the trial center as a 
resource and support is valuable and 
therapeutic to  carers (Mastwyk et al., 
2002) as is follow-up after a trial (Mad- 
sen et al., 2000). Despite lengthy visits 
required by Alzheimer’s disease (AD) 
treatment trials and a lack of physical or 
emotional improvement in the patient 
as perceived by the carer, carers do not 
find study visits a chore, but rather a 
positive experience (Braunholtz et al., 
2001; Mastwyk et al., 2002). Anticipation 
of a treatment effect does not appear to 
be a prime motivator in the carer’s and 
patient’s decision to  enroll, nor is the 
risk of adverse effects of the study drug 
a deterrent (Karlawish et al., 2002). 
Given that clinical trials sometimes play 
a central role in the management of peo- 
ple with AD, it is important that due con- 
sideration be given to  the provision of 
adequate follow-up for those who do not 
meet screening criteria and for those 
who leave a study following its comple- 
tion (Mastwyk et al., 2002). 
The Mental Health Research Insti- 
tute (MHRI) and National Ageing 
Research Institute (NARI) have been 
conducting clinical treatment trials for 
AD for several years now. Some time 
ago we began to investigate how 
involvement in these trials was per- 
ceived by participants (both patients 
and carers) (Mastwyk et  al., 2002). In 
the current study, we continued this 
line of investigation and integrated 
those who did not meet study entry 
criteria: What were their perceptions 
and experiences? 
We conducted a retrospective survey 
of people who presented for inclusion 
in a clinical trial sponsored by a 
biotechnology company (Prana 
Biotechnology, South Melbourne, Aus- 
tralia) to  ascertain if their needs and 
expectations were fulfilled. How accept- 
able was our conduct in the screening 
and management of these people? Did 
we perform ethically? Did we give 
appropriate attention to people accept- 
ed/not accepted? This study differs 
from our previous work in that we were 
able to compare the impressions of two 
distinct groups: those randomized to 
the study and those who were not 
included. 
This particular clinical trial was simi- 
lar to other clinical trials for AD in 
terms of the requirement for the patient 
and carer to attend 4-weekly safety 
assessments and 12-weekly efficacy 
assessments. However, at the 12-weekly 
visits, plasma sampling for drug phar- 
macokinetics was conducted at  2- 
hourly intervals over 6 hours. In this 
respect, this drug trial was more 
demanding of the research volunteers’ 
time, and was indeed more tiring, than 
most studies. 
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METHOD 
Fifty-eight patients, with their carers, 
attended the MHRI seeking to be includ- 
ed in a single-center, proof-of-concept, 
clinical treatment trial for AD. This was 
the Prana-sponsored clioquinol study 
that received much media publicity in 
Australia and was hypothesized t o  
reduce AP in the brains of people with 
AD. The study was double-blind and all 
patients had been taking Aricept for a 
minimum of 6 months. Most patients 
were referred by their carer, who had 
heard about the trial through the media. 
Following the conclusion of this trial, 
two questionnaires were drafted: one 
directed to carers of patients who were 
enrolled into the study (n = 36), the 
other to carers of patients who did not 
meet study entry criteria (herein 
referred to as the screening-only group; 
R = 22). Both questionnaires were devel- 
oped with input from clinicians experi- 
enced in the specialized treatment of 
people with AD. The content was 
designed to reflect variables that have 
been shown previously to  have an effect 
on AD patients and their carers’ experi- 
ence of the health care they receive 
(such as the amount of time required to  
attend hospital visits) and attempted to 
incorporate feedback from trial partici- 
pants that had previously been noted 
anecdotally. Where possible, half of the 
items per question were negatively 
worded to minimize response bias. The 
questionnaire was sent with a letter of 
explanation and reply-paid envelope, 
return indicating consent. The demo- 
graphic data sought were general and 
designed to not reveal the carer’s iden- 
tity. The questionnaires asked similar 
questions regarding previous clinical 
trial experience, how the carers found 
out about the trial, and their hopes of 
trial involvement. The questionnaires 
differed in asking how the carer felt at 
the end of completing the study (for the 
randomized group) and how he or she 
felt after not being accepted into the 
study (for the screening-only group). 
The questionnaires also gave carers the 
opportunity to add to  the information 
given through a series of open-ended 
questions. Both questionnaires were 
sent on NARI letterhead, signed by a cli- 
nician unknown to the recipients (D. L.) 
to  minimize response bias. 
RESULTS 
Demographics 
Eighty-one percent (29/36) of question- 
naires were returned from the random- 
ized group, and 68% (15/22) from the 
screening-only group. 
The carers of those not included were 
older (69 vs. 62), had spent more time 
caring for the patient (4.6 years vs. 4.0 
years), were better educated (57% terti- 
ary vs. 33%), and were more often pro- 
fessionally employed (60% vs. 30%) than 
those carers who entered the trial. How- 
ever, these differences failed to reach sta- 
tistical significance. 
There was no difference in regard to 
illness duration of the patients. Those 
who were not included were older (76.9 
years vs. 72 years), were better educat- 
ed (39% tertiary vs. 26%), were more 
often professionally employed (40% vs. 
29%), and tended to have retired at a 
later age (60 vs. 55), although again 
these differences were not statistically 
significant. Both groups were similar in 
terms of their previous participation in 
clinical trials, whether they would do so 
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TABLE 1. Carer Demographics 
Carers 
Questionnaires returned 
Ave. time caring 
Ave. age 
Relationship to patient 
Gender 
Education-tertiary 
Professional employment 
Retirement to care for patient 
Ave. age 
Ave. time since AD diagnosis 
Gender 
Education 
Patients 
Professional employment 
Retirement due to AD 
Ave. retirement age 
Living with carer 
Randomized Group Screening-Only Group 
(n = 36) (n = 22) 
81% (29) 
4.0 years (SO 1.7) 
62 (SO 11.2) 
72% (21) spouses 
69% (20) female 
30% (6) 
26% (5) 
33% (17) 
72 (SO 8.7) 
4.7 (SO 1.6) 
59% (17) Male 
26% (7) tertiary; 
55% (16) 9-12 years 
29% (8) 
21% (5) 
55 (SO 12) 
62% (16) 
68% (15) 
4.6 years (SO 3.32) 
69 (SD 13.24) 
80% (12) spouses 
60% (9) female 
57% (8) 
60% (9) 
20% (2) 
76.9 (SO 6.78) 
4.72 years (SO 3.95) 
47% (7) male 
39% (5) tertiary; 
54% (7) 9-12 years 
40% (6) 
15% (2) 
60 (SO 9.42) 
67% (10) 
Note. Ave. = average; AD = Alzheimer’s disease. 
TABLE 2. Trial Knowledge and Experience 
Randomization Group Screening-Only Group 
Previous clinical trial experience? 24% (7) 20% (3) 
Do it again? 67% (18) 77% (10) 
Media 55% (16) 47% (7) 
Recommend it to others? 97% (28) 100% (14) 
Knowledge of trial 
GP 7% (2) 13% (2) 
Friend/relative 17% (5) 13% (2) 
Note. GP = general practitioner. 
again, whether they would recommend 
participation, and how they heard 
about the trial. 
Both groups felt the screening visit 
provided them with adequate informa- 
tion about the study: what they could 
expect, what would be expected of 
them, the risks and benefits of the study 
drug. All reported that enough time was 
allowed to make their decision. They 
were satisfied with the information pro- 
vided at screening and viewed the  
screening visit as a positive experience. 
Carers were motivated to participate 
in a clinical trial with their relative in 
order to help their relative feel better or 
live longer, to improve the health of oth- 
ers, and to contribute to medical science. 
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TABLE 3. Reasons for Participating Qtated Extremely or Moderately Important) 
Randomized Group Screening-Only Group 
(n = 29) (n = 15) 
Help relative feel better 93% (14 of 15 respondents) 
Help relative live longer 93% (14 of 15) 
Improve health of others 85% (12 of 14) 
Contribute to medical science 92% (23 of 26) 80% (12) 
Mildly important 20% (3) 
Family/friends 35% (7 of 20) 42% (5 of 12) 
Not important at all 25% (5) Not important at all 42% (5) 
Doctor recommended it 18% (3 of 17) 54% (6 of 11) 
Not important at all 65% (4) 
Free specialist care and 17% (4 of 23) 39% (5 of 13) 
Not important at all 61% (14) Not important at all 39% (5) 
Having someone to talk to 65% (15 of 23) 36% (4 of 11) 
Not important at all 9% (4) Not important at all 36% (4) 
The hope that the drug 93% (25 of 27) 79% (11 of 13) 
Note. Carers were selective in answering these questions. Number of respondents indicated in parentheses follow- 
ing percentages. 
96% (26 of 27 respondents) 
73% (19 of 26) 
96% (23 of 24) 
recommended it 
attention 
would cure my relative 
- - 
Both groups hoped that the drug would 
“cure” their relative. Few (9/28) respon- 
dents felt that their local doctor’s opinion 
regarding the clinical trial was an influen- 
tial factor in their decision to participate, 
while a significant number of the ran- 
domized group rated the availability of 
trial personnel as “people they could talk 
to” an important factor in their decision 
to participate. 
Impressions at End of Trial 
Randomized Group. At the end of 
the study, 60% of respondents in the 
randomization group feIt their relative 
was no better; 59% were concerned 
their relative might be on placebo; 50% 
reported that the investigators had 
made recommendations for them to 
pursue after trial participation if they 
wished; 47% reported that they were 
referred for ongoing care; 44% had 
received counseling from the investiga- 
tors; 35% were pleased to finish the 
trial; 22% felt the visits were becoming a 
chore; and only 6% felt abandoned. 
Ninety-four percent of respondents 
felt they could contact staff in the 
future; 92% reported that their overall 
participation was an extremely/moder- 
ately positive experience; 84% would 
miss staff contact; 64% of carers felt 
emotionally better; 53% were sad to  fin- 
ish; 32% of patients felt emotionally bet- 
ter; 75% felt their expectations as a 
whole were extremely/moderately well 
met. 
Screening-Only Group. (Respon- 
dents on average answered 66% of 
questions.) Although the majority of 
respondents felt displeased, disap- 
pointed, or upset at not being included 
and felt that their relative’s health 
would suffer as a result, only a small 
proportion (2 of 10 responses to  this 
question) felt it unfair their relative was 
not included. N o  respondents reported 
feeling angry, abandoned, or used at 
having failed the  screening visit. 
Indeed, most felt that the reasons for 
exclusion were clearly explained, that 
staff were helpful, and that the screen- 
ing visit improved their understanding 
of AD. Half felt that they would be able 
to use the staff as  a resource for help in 
the future. 
Respondents in both groups reported 
that participation in the screening visit 
was an extremely/moderately positive 
experience and that their expectations 
of this visit were extremely/moderately 
well fulfilled. There were no significant 
group differences in terms of previous 
trial experience; willingness to  partici- 
pate again; likelihood to recommend 
participation to others; how they heard 
about the trial; why they chose to par- 
ticipate; satisfaction with information 
given at screening; and the likelihood to 
have viewed the screening visit as a 
positive experience. 
Most contributions to the open-ended 
questions echoed responses in the 
questionnaire: reiterating a wish to help 
others, particularly future generations; 
improving the  quality of life of the 
patient; contributing t o  scientific 
research; and appreciation of the sup- 
port and care offered by study staff. 
However, where we seem to have failed 
was in the provision of information to 
general practitioners. Most responses to 
the question “Do you think adequate 
information or feedback has been 
passed onto the patient’s local doctor? 
In regard to: the trial? the patient’s 
progress? study results?” were either 
“don’t know” or negative. Responses 
ranged from “No” to “While the research 
doctor was quick in picking up small 
health problems and informing the local 
doctor to check into [sic], I myself felt 
by the questions asked by the local doc- 
tor, that he was not getting full feedback 
on the trial” and “Not to date. I feel reg- 
ular feedback would have been helpful 
and reassuring (perhaps every 8 weeks 
or so).” Forty-one percent of responses 
to this question were positive. 
Carers were also asked the question 
“If counseling had been offered, would 
you have taken it?” Despite not being 
offered counseling, most respondents 
from the screening-only group said that 
they would not have taken it up if it 
were. Carers from the randomized group 
responded, in the main, that counseling 
was not required; the care and attention 
they received from the research staff 
satisfied their needs in this regard. 
DISCUSSION 
This study supports the findings of pre- 
vious studies suggesting that research 
volunteers approach clinical trials 
altruistically (Elad et al., 2000; Madsen 
et  al., 2000; Terenius, ZOOO), feel a need 
to do  anything possible for their rela- 
tive (Karlawish et al., ZOOl), and view 
the research center as an important 
source of support and information for 
carers (Elad et al., 2000; Mastwyk et al., 
2002). This study also adds to our 
knowledge by providing a profile of 
potential study participants and gives 
an indication of how to  make contact 
with research volunteers. 
Despite feeling disappointed and 
upset at not being included in the study, 
carers from the screening-only group 
felt that they benefited from their expe- 
rience at the  screening visit. Their 
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knowledge of AD improved and they felt 
they could contact the trial center at a 
future date if they required help. 
Our enquiry regarding our ethical 
conduct of the study is, perhaps, 
addressed by those carers who did not 
continue with us, reporting their experi- 
ence at the institute as a positive one. 
Carers who completed the clinical trial 
with their relative also responded posi- 
tively. Although questions of ethical 
conduct are always difficult to address, 
positive responses can only reflect sat- 
isfaction with their research experience. 
The finding that carers and patients in 
the screening-only group were older than 
the randomized group may indicate that 
greater age correlates with greater 
comorbidity, more concomitant medica- 
tions, and (arguably) more advanced dis- 
ease, all of which contribute to  an 
increased likelihood of failing screening. 
The finding of greater rates of tertiary 
education and professional employment 
among carers whose relatives were not 
included may reflect a greater degree of 
motivation/effort to access assistance for 
their relative, thus leading to  an 
increased likelihood of presenting for 
screening (despite unsuitability). In addi- 
tion, similar illness duration in both 
groups in the setting of higher education, 
professional employment, an older age, 
and later retirement age of the screening- 
only group perhaps gives credence to the 
adage “use it or lose it.” 
Even though trial participation was 
onerous and patients were generally 
perceived as not having improved, car- 
ers still felt their participation was a 
positive experience and their expecta- 
tions were met. This is consistent with 
the hypothesis that although carers 
may often enter a trial with unrealistic 
hopes (of a cure, for example), their 
expeckzations are more realistic. 
The interesting finding that fewer car- 
ers would repeat the experience than 
would recommend it to  others may 
reflect the severity of illness of the 
patient at the conclusion of the trial, 
precluding the demanding requirements 
of further clinical trial participation. The 
ongoing provision and availability of the 
clinical trial center as a resource and the 
support received through regular staff 
contact are seen as valuable by carers. 
Despite the investigators ’ knowledge 
that there are many people in the com- 
munity who meet the criteria for clinical 
trials who would be agreeable to partic- 
ipation, finding them is never easy. 
Information letters to specialists and 
general practitioners notifying them of 
studies produce few referrals. We have 
found that the most fruitful source of 
recruitment is via media publicity, and 
this source was ranked as primarily 
responsible for information about the 
clinical trial by the carers in this study. 
In regard to forwarding information to 
the patient’s general practitioner, per- 
haps we have not acted in the interests 
of the patient, being quick to request 
information and documentation at the 
time of screening, yet lacking when it 
comes to passing on information regard- 
ing the patient’s progress in return. We 
recommend that trial protocols be con- 
structed to include defined mechanisms 
for communicating with primary care 
physicians, to ensure that feedback is 
adequate and that this effort to feedback 
information to general practitioners be 
conveyed to trial participants. 
Perhaps these findings cannot be gen- 
eralized to other sites conducting clini- 
cal research. Ours is a research-specific 
institute where, in the main, carers and 
patients refer themselves for trial partic- 
ipation. Their motivation thus tends to 
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be high. Experiences of patients and car- 
ers at general hospitals and in other 
countries and health systems are likely 
to be different, although this is an empir- 
ical question and could be the subject of 
future research. However, the thorough- 
ness with which the study and its 
requirements were described, together 
with the open-ended offer of access to 
staff as a resource, may be utilized in all 
settings for the benefit of trial partici- 
pants. This approach could contribute 
to the development of a positive reputa- 
tion for any research site and may assist 
recruitment for future research studies. 
Future research could include a prospec- 
tive questionnaire at baseline with a fol- 
low-up at the end of the study, which 
together could offer other insights into 
the motivation and expectations of trial 
participants. 
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